Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
Myriad Genetics (NASDAQ:MYGN), a molecular diagnostic testing and precision medicine company, announced its participation in two upcoming healthcare investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Myriad Genetics (NASDAQ:MYGN), a molecular diagnostic testing and precision medicine company, announced its participation in two upcoming healthcare investor conferences. Management will present at the Wells Fargo Healthcare Conference on September 4, 2025, at 3:45 PM ET and the Morgan Stanley Annual Global Healthcare Conference on September 10, 2025, at 7:45 AM ET. Both presentations will be available via webcast on the company's investor relations website.
Details
News Market Reaction – MYGN
On Aug 28, the first trading day after this news, MYGN closed 4.89% above the previous close.
Data tracked by StockTitan Argus for the Aug 28 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SALT LAKE CITY, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced Myriad management will participate in two upcoming healthcare conferences.
- The Wells Fargo Healthcare Conference with a fireside chat on Thursday, Sept. 4 at 3:45pm ET.
- The Morgan Stanley Annual Global Healthcare Conference with a fireside chat on Wednesday, Sept. 10 at 7:45am ET.
Links to the live and archived webcasts of both presentations can be viewed at investor.myriad.com.
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.
Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com
Media Contact
Kate Schraml
(224) 875-4493
PR@myriad.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.